Inactive Instrument

Insiders Mateon Therapeutics Inc Nasdaq

Equities

Oncotelic Therapeutics, Inc. Announces Executive Changes	02/23/02	CI
Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer	04/22/04	CI
Oncotelic Therapeutics, Inc. Appoints Fatih Uckun as Chief Medical Officer	03/22/03	CI
Oncotelic Therapeutics, Inc. has Changed its Name to MATEON THERAPEUTICS, INC	30/21/30	CI
Mateon Therapeutics Appoints Giancarlo Mennella to Lead Licensing Activity for Trabedersen (OT-101) for COVID-19 Globally	09/20/09	CI
Mateon Therapeutics, Inc. Appoints Dr. Anthony Maida as Chief Clinical Officer - Translational Medicine	07/20/07	CI
Mateon Therapeutics, Inc. Appoints Steven W. King and Anthony E. Maida, III to the Board of Directors	15/20/15	CI
Mateon Therapeutics, Inc. Announces Board Changes	23/20/23	CI
Mateon Therapeutics, Inc. Announces Resignation of Dr. Fatih Uckun as Chief Medical Officer	07/20/07	CI
Oncotelic Inc. Names John H. Sampson to its Medical Advisory Board	16/19/16	CI
Mateon Therapeutics, Inc. Announces Executive Changes	13/19/13	CI

No results for this search